Tanja Trarbach

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

David Malka, Pascale Cervera, Stéphanie Foulon et al. · The Lancet Oncology · 2014 · 409 citations · Full text

Advanced Biliary-tract Cancer, Gastrointestinal Oncology, Medicine +7

Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor

U. Vanhoefer, Mitra Tewes, Federico Rojo et al. · Journal of Clinical Oncology · 2003 · 259 citations

Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)

Gunnar Folprecht, Thomas Gruenberger, Wolf O. Bechstein et al. · Annals of Oncology · 2014 · 258 citations · Full text

Surgical Oncology, Hepatology, Gastrointestinal Oncology +10

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial

Susanna Hegewisch‐Becker, Ullrich Graeven, Christian Lerchenmüller et al. · The Lancet Oncology · 2015 · 246 citations

Maintenance Strategies, Aio 0207, Medicine +7

Operations for Intrahepatic Cholangiocarcinoma: Single-Institution Experience of 158 Patients

Hauke Lang, Georgios C. Sotiropoulos, George Sgourakis et al. · Journal of the American College of Surgeons · 2009 · 201 citations